- Home
- ZVSA
as 11-15-2024 4:00pm EST
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SOMERVILLE |
| Market Cap: | 2.3M | IPO Year: | N/A |
| Target Price: | $240.00 | AVG Volume (30 days): | 3.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -43.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.05 - $42.35 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ZyVersa Therapeutics Inc. News
ZVSA Breaking Stock News: Dive into ZVSA Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
GlobeNewswire
4 days ago
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
GlobeNewswire
6 days ago
Life Sciences Investor Forum Agenda Announced for November 14th
MT Newswires
13 days ago
ZyVersa Says Data Show Inflammasome Inhibition May Slow Obesity-Linked Diabetes; Shares Jump
MT Newswires
13 days ago
Top Premarket Gainers
GlobeNewswire
13 days ago
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
GlobeNewswire
20 days ago
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs
GlobeNewswire
a month ago
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
Compare ZVSA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZVSA ZyVersa Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.